menu search

CODX / CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?

CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. Read More
Posted: Jun 24 2022, 07:50
Author Name: Zacks Investment Research
Views: 111599

CODX News  

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 10, 2023

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to more_horizontal

Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast

By PRNewsWire
July 27, 2023

Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast

SALT LAKE CITY , July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform f more_horizontal

Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 11, 2023

Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relat more_horizontal

Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 11, 2023

Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to more_horizontal

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

By Zacks Investment Research
March 16, 2023

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the more_horizontal

Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 16, 2023

Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor R more_horizontal

CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST

By PRNewsWire
March 9, 2023

CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform f more_horizontal

Co-Diagnostics ends 3Q with $86.5M in cash; makes significant progress on its Co-Dx PCR Home platform

By Proactive Investors
November 11, 2022

Co-Diagnostics ends 3Q with $86.5M in cash; makes significant progress on its Co-Dx PCR Home platform

Co-Diagnostics Inc (NASDAQ:CODX) posted financial results for the third quarter that revealed ample cash on hand, giving the company scope to further more_horizontal


Search within

Pages Search Results: